Mirabegron/solifenacin

Drug Profile

Mirabegron/solifenacin

Alternative Names: EB 178; Solifenacin/mirabegron; YM178/YM905

Latest Information Update: 04 Jul 2017

Price : $50

At a glance

  • Originator Astellas Pharma Europe Ltd
  • Class Antispasmodics; Quinuclidines; Small molecules; Thiazoles; Urologics
  • Mechanism of Action Beta 3 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Overactive bladder

Most Recent Events

  • 29 Jun 2017 Preregistration for Overactive bladder in USA (PO)
  • 01 Sep 2016 Astellas Pharma completes the SYNERGY II trial in Overactive bladder in US, Australia, Belgium, Bulgaria, Canada, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Poland, Romania, Russia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sweden, Thailand, Ukraine and United Kingdom (NCT02045862)
  • 31 Jan 2014 Astellas Pharma initiates the phase III SYNERGY II trial in Overactive bladder in Italy and Estonia (EudraCT2012-005736-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top